Trace Neuroscience vs Earendil Labs
Side-by-side comparison of AI visibility scores, market position, and capabilities
Launched with $101M Series A (Third Rock, Atlas, GV, RA Capital). TRCN-1023 (ASO for UNC13A mRNA splicing) entered ALS clinical testing in early 2026 — skipping healthy volunteer phase. Targets 97% of ALS patients.
About
Trace Neuroscience launched with $101 million in Series A financing from Third Rock Ventures, Atlas Venture, GV (Google Ventures), and RA Capital Management, developing TRCN-1023 — an antisense oligonucleotide (ASO) that corrects UNC13A mRNA splicing defects that have been genetically validated as a driver of ALS (amyotrophic lateral sclerosis). The company went directly to ALS patient enrollment in early 2026, bypassing the healthy volunteer phase typical of first-in-human trials, reflecting confidence in the mechanism's tolerability profile.
Full-stack AI biologics company raised $787M in Mar 2026 backed by Sanofi, Pfizer/Hillhouse, and DST Global; $2.56B Sanofi collaboration signed Jan 2026; platform generates 40+ AI-designed protein therapeutics across multiple therapeutic areas.
About
Earendil Labs is a full-stack AI biologics company that uses a proprietary AI platform to design protein therapeutics at scale. The company secured $787 million in financing in March 2026, backed by Sanofi, the Pfizer-Hillhouse Biotech Fund, Dimension Capital, and DST Global — one of the largest AI drug discovery raises in the industry's history.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.